HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Conditions:   Metastatic Breast Cancer;   Locally Advanced Breast Cancer;   Advanced Breast Cancer;   BRCA2 Mutation;   BRCA1 Mutation
Interventions:   Drug: Palbociclib;   Drug: Olaparib;   Drug: Fulvestrant
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 20, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments